Roquefort Investments PLC Corporate Update (5009F)
19 Julio 2021 - 1:00AM
UK Regulatory
TIDMROQ
RNS Number : 5009F
Roquefort Investments PLC
19 July 2021
19 July 2021
roquefort investments PLC
("Roquefort Investments" or the "Company")
Corporate Update
Roquefort Investments plc, an investment company established to
acquire businesses focused on early-stage opportunities in the
medical biotechnology sector, provides the following corporate
update.
Further to the admission of the Company's shares to the Official
List by way of a standard listing and to trading on the London
Stock Exchange in March 2021, the Company has been progressing the
formal screening of various compelling opportunities in line with
its stated objective of acquiring a biotechnology business that is
in the "research" or "pre-clinical development" stage in the
medical sector. Whilst the Company is at an early stage in such
process, the Board is encouraged by the initial due diligence it
has initiated.
The Company has not been negatively impacted by the ongoing
COVID-19 pandemic and believes it will ultimately benefit from the
increased market focus on the medical biotechnology industry in the
current environment.
Roquefort Investment's business model is well tailored to the
current climate in terms of maintaining low overheads to preserve
cash, seeking early-stage established businesses in the medical
biotechnology industry enabling a cost-effective entry point to
compelling opportunities, and utilising the commercial and
technical capabilities of its management team to progress
opportunities internally.
Stephen West, Chairman of Roquefort Investments, commented:
"The current environment has undoubtedly led to more
opportunities in the exciting biotechnology sector coming to our
attention, which we have now high-graded in order to focus on the
most compelling. These high-graded opportunities are fully
consistent with our strategy and we are most encouraged by the
progress we are making with our initial due diligence discussions.
We hope to provide a more detailed update in due course as these
discussions progress further and we have narrowed down our
selection to an appropriate target."
Enquiries:
Roquefort Investments plc
+44 (0)20 3290
Stephen West (Chairman) 9339
Optiva Securities Limited (Broker)
+44 (0)20 3411
Christian Dennis 1881
For further information, please visit www.roquefortinvest.com
and @roquefortinvest on Twitter.
About Roquefort Investments
Roquefort Investments was formed as an investment company to
acquire businesses focused on early-stage opportunities in the
medical biotechnology sector with the aim of generating optimal
returns for both the target businesses and our shareholders. It is
envisaged that such acquisition or acquisitions will trigger a
reverse takeover in accordance with the listing rules.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDBGGDRRDBDGBL
(END) Dow Jones Newswires
July 19, 2021 02:00 ET (06:00 GMT)
Roquefort Therapeutics (LSE:ROQ)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Roquefort Therapeutics (LSE:ROQ)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024